Twelve vs 24 Months of Dual Antiplatelet Therapy in Patients With Coronary Revascularization for In-stent Restenosis
Condition(s):Percutaneous Coronary InterventionLast Updated:March 30, 2015Unknown status
Hide Studies Not Open or Pending
Condition(s):Percutaneous Coronary InterventionLast Updated:March 30, 2015Unknown status
Condition(s):Pharmacogenetics; Drug-Related Side Effects and Adverse Reactions; Cardiovascular DrugsLast Updated:April 1, 2022Recruiting
Condition(s):In-stent RestenosisLast Updated:October 19, 2023Not yet recruiting
Condition(s):Coronary Artery DiseaseLast Updated:May 5, 2015Completed
Condition(s):Acute Coronary Syndrome; Percutaneous Coronary Intervention; Drug-Eluting StentsLast Updated:June 23, 2017Completed
Condition(s):Coronary Artery Disease; Drug Interaction PotentiationLast Updated:July 6, 2018Completed
Condition(s):Coronary Artery DiseaseLast Updated:October 10, 2012Completed
Condition(s):Acute Coronary Syndrome; STEMI; NSTEMI – Non-ST Segment Elevation MI; PLATELET AGGREGATION; INDIVIDUALIZED THERAPYLast Updated:April 30, 2020Completed
Condition(s):Atrial FibrillationLast Updated:May 6, 2020Completed
Condition(s):Myocardial Infarction; STEMILast Updated:May 10, 2019Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.